Últimas noticias sobre NuCana (NASDAQ:NCNA) Bolsa

NuCana

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

NuCana PLC

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform and raises the price target from $183 to $190.

News

Price Target

Analyst Ratings

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Raises Price Target to $190

Trading Ideas

ASML

MSCI

Third Point 13F Shows Exited Position In International Flavors & Fragrances, Previously Holding 1,300,000 Shares; Advance Auto Parts, Previously Holding 1,500,100 Shares; ASML Holding, Previously Holding 80,000 Shares; MSCI, Previously Holding 150,000 Shares; Micron Technology Inc, Previously Holding 275,000 Shares

Earnings

Retractable Technologies Q3 Sales $10.3M, Flat YoY

Federal Reserve Chair Jerome Powell's unexpectedly hawkish remarks on Thursday sent markets into a tailspin. Major U.S. equity indices closed in the red, and the dollar soared for <a href="https://www.benzinga.com/topic/interest-rates">a fifth consecutive session</a>.
In a speech to Dallas business leaders, Powell highlighted the remarkable strength of the U.S. economy, indicating that there's no need for the Fed to &#8220;be in a hurry to lower rates.&#8221;
He reiterated the central bank's commitment to reaching its 2% inflation target, stressing the need for careful decision-making as inflation remains above desired levels.
He highlighted productivity gains, which he said have &#8220;grown faster over the past five years than at any point in the two decades preceding the pandemic,&#8221; positioning the U.S. economy as &#8220;the best-performing among major economies.&#8221;
Addressing the October <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">producer price index (PPI) uptick</a>, Powell labeled it &#8220;more than an upward bump&#8221; but maintained confidence in the trajectory toward the 2% inflation goal.
<h3 class="wp-block-heading">Markets Reassess Interest Rate Path: Traders Are Less Confident On A December Cut</h3>
Powell&#8217;s comments impacted the interest-rate market, with fed futures now reflecting a reduced likelihood of a 25-basis-point cut in December. 
The CME FedWatch tool shows the odds of such a move dropped to 58%, sharply down from around 80% earlier in the day.
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed down 0.6%, fully erasing gains from last week&#8217;s rate cut. Energy was the only sector in positive territory, rising 0.4%, while industrials and health care led declines, each down 0.7%.
Top performers in the S&amp;P 500 included Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), and First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), which rose 12.8%, 8.7%, and 7.2%, respectively. Among the laggards were Leidos Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) and Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), down 13.6% and 11.4%, respectively.
Tech stocks, as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), declined 0.7%, marking a fourth consecutive loss. Blue chips followed by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) slipped 0.5%, while small caps in the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) underperformed, falling 1.3%.
The dollar continued to attract liquidity, with the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) logging a fifth consecutive gain, reaching levels last seen in late October 2023.
Treasury yields also rose, with the 10-year yield closing at 4.46%. Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), marked its fifth straight loss.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was 1.7% lower in the past 24 hours to $88,013 at 5:21 p.m. ET, on track for its worst day in November.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984852/trumps-red-wave-pushes-emerging-market-stocks-to-2-month-lows-volatility-expected-to-remain-elevated">Trump&#8217;s Red Wave Pushes Emerging Market Stocks To 2-Month Lows: Volatility &#8216;Expected To Remain Elevated&#8217; </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Bonds

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Currency ETFs

Treasuries

Economics

Federal Reserve

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

FSLR

LDOS

SMCI

PowerShares DB US Dollar Index Bullish Fund

WYNN

Powell's Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips

WIIM

TMC Metals shares are trading higher. The company reported Q3 financial results.

Telsey Advisory Group analyst Cristina Fernandez upgrades Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) from Market Perform to Outperform and raises the price target from $11 to $12.

Upgrades

ARHS

Telsey Advisory Group Upgrades Arhaus to Outperform, Raises Price Target to $12

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.57) by 10.53 percent.

Earnings Beats

BCLI

Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate

TIVC

Tivic Health Systems shares are trading lower after the company reported a year-over-year decline in Q3 sales results.

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and maintains $12 price target.

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $12 Price Target

OCTO

Eightco Holdings Q3 Sales $7.7M Down From $23.3M YoY

Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) reported quarterly losses of $(8.81) per share which missed the analyst consensus estimate of $(6.12) by 43.95 percent. The company reported quarterly sales of $57.000 million which beat the analyst consensus estimate of $58.000 thousand by 98.18K percent.

Earnings Misses

TRAW

Traws Pharma Q3 2024 GAAP EPS $(8.81) Misses $(6.12) Estimate, Sales $57.000M Beat $58.000K Estimate

GOOGL

UBER

Third Point 13F Shows Exited Position In Alphabet, Previously Holding 1,980,000 Shares; American Intl Group, Previously Holding 3,450,000 Shares; Verizon Communications, Previously Holding 4,675,000 Shares; Uber Technologies Inc, Previously Holding 2,100,000 Shares; KB Home, Previously Holding 2,100,000 Shares

Billionaire investor Warren Buffett cut several of Berkshire Hathaway Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) <a href="https://www.benzinga.com/markets/equities/24/08/40232279/is-warren-buffett-bearish-or-waiting-to-pounce-berkshire-now-owns-more-t-bills-than-federal-rese">largest holdings this year</a>. 
The Omaha, Nebraska-based holding company&#8217;s latest 13F filing shows that the sell-off trend continues.
What Happened: Berkshire&#8217;s latest 13F filing, filed on Thursday, reflects the company&#8217;s largest holdings as of September 30.
Buffett reduced his stake in Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from 400 million to 300 million shares. Thus, Berkshire has now cut its position in the Cupertino, California-based tech giant by over two-thirds since 2023&#8217;s third quarter.
The Omaha &#8220;oracle&#8221; also continued to cut his stake in Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), trimming back another 23% of Berkshire&#8217;s position.
Berkshire cut nearly all of its position in Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>). Buffett <a href="https://www.benzinga.com/markets/equities/24/08/40385824/warren-buffett-still-holds-400m-apple-shares-reveals-new-investments-in-ulta-beauty-and-heico-el">revealed a position in the cosmetic store chain</a> in August; the company&#8217;s stock has performed roughly even since then. Buffett&#8217;s Ulta holding period was unusually short for the famed value investor.
Meanwhile, Buffett added a couple of fresh faces to Berkshire&#8217;s portfolio.
Buffett bought 1,277,256 shares of Ann Arbor, Michigan-based pizza chain Domino&#8217;s Pizza Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>). He also made a foray into pool equipment, buying 404,057 shares of Pool Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>).
Price Action: Investors quickly reacted to Berkshire&#8217;s 13F filing after hours:
<ul>
<li>Dominoes Pizza shares traded up nearly 7%.</li>
<li>Pool Corp shares traded up nearly 6%.</li>
<li>Ulta Beauty shares fell over 4%.</li>
<li>Apple and Bank of America shed insignificant portions of their market value.</li>
</ul>
Why it Matters: During Berkshire&#8217;s annual shareholder meeting in May, Buffett hinted that his sell-offs were a result of tax implications. 
This <a href="https://www.benzinga.com/markets/equities/24/08/40385824/warren-buffett-still-holds-400m-apple-shares-reveals-new-investments-in-ulta-beauty-and-heico-el">has not stopped</a> investors&#8217; conjecture that Buffett is perhaps bearish <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">on the market at large</a>.
Alternatively, Buffett could be simply trimming positions that take up an outsized portion of Berkshire&#8217;s portfolio to reduce exposure.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Image via Flickr

AAPL

POOL

ULTA

Warren Buffett's Berkshire Hathaway Slashes Apple, BofA Holdings, Adds Domino's Pizza In Q3

LGCY

Legacy Education shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent.

BNTC

Benitec Biopharma Q1 2025 GAAP EPS $(0.48) Beats $(0.55) Estimate

MLSS

Milestone Scientific shares are trading higher after the company reported better-than-expected Q3 financials.

Hedge Funds

General

MRCY

Starboard Value's Q3 2024 13F Filing Reveals Complete Exits From Mercury Systems With 2.29M Shares, AECOM With 625K Shares

BENF

Beneficient shares are trading higher after the company reported a year-over-year increase in Q2 revenue results.

OPTX

Syntec Optics Holdings Q3 EPS $0.00 Down From $0.01 YoY, Sales $7.86M Up From $6.6M YoY

Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest <a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957424006690/xslForm13F_X02/infotable.xml">Form 13F</a> on Thursday and disclosed its trading activity from the prior quarter. Here's a look at Tiger Global's <a href="https://www.benzinga.com/opinion/24/08/40422936/steal-these-two-stock-ideas-from-the-best-investors-in-the-world">portfolio changes.&nbsp;</a>
The Details: Tiger Global has $23.439 billion in assets under management and made no changes to its top five holdings:&nbsp;
<ul>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) </li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) </li>
<li>Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) </li>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) </li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) </li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
New Positions: Tiger Global opened three new positions including a $801.3 million stake in Flutter Entertainment Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), the parent company of FanDuel. The fund also opened a $201.4 million position in Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) and a $48.9 million position in South Korean e-commerce platform Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>). 
Notable Trades: Tiger Global added 564,090 shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to its portfolio, bringing its total number of shares owned to 3,634,980. The fund also increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) by 195,714 shares, bringing its current holdings to 5,839,256 shares valued at $897.5 million. 
Closed Positions: The hedge fund closed out its positions in Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) and DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image created using artificial intelligence via MidJourney.

Movers

ALAB

CPNG

DXCM

FLUT

MSFT

TTWO

Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom

NuCana plunges after trial setback for cancer drug

Nucana (NCNA) has released an update. NuCana plc showcased positive results from its Phase 2 study of NUC-7738 in combination with pembrolizumab, o...

NuCana Reports Breakthrough in Resistant Melanoma Treatment

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00. The company'...

Oppenheimer Sticks to Their Buy Rating for Nucana (NCNA)

NuCana soars on positive data from mid-stage trial for its melanoma treatment

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company's shares closed yesterd...

Truist Financial Keeps Their Buy Rating on Nucana (NCNA)

Nucana (NCNA) has released an update. NuCana plc has announced the US Patent and Trademark Office granted a new patent for NUC-7738, a novel anti-c...

NuCana Secures US Patent for Promising Cancer Drug

Nucana (NCNA) has released an update. NuCana plc has updated its Prospectus Supplement to increase the maximum aggregate offering amount to $5.4 mi...

NuCana plc Enhances Offering to $5.4 Million

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nucana (NCNA – Research Report), with a price...

Truist Financial Sticks to Their Buy Rating for Nucana (NCNA)

NuCana (NCNA) announced that initial data from the ongoing Phase 1b/2 modular study investigating NUC-3373 in combination with the PD-1 inhibitor p...

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

Nucana (NCNA) has released an update. NuCana's recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination wi...

NuCana's NUC-3373 Shows Promise in Cancer Treatment

NCNA

RHHBF

RHHBY

Press Releases

NuCana Announces Completion of ADS Ratio Change

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

Health Care

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Legal

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Comments

NuCana

Noticias

Últimas noticias sobre NuCana (NASDAQ:NCNA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL